04:52 PM EDT, 07/29/2024 (MT Newswires) -- Corcept Therapeutics ( CORT ) reported Q2 net income late Monday of $0.32 per diluted share, up from $0.25 a year earlier.

Four analysts polled by Capital IQ expected EPS of $0.22.

Revenue for the quarter ended June 30 was $163.8 million, up from $117.7 million a year earlier.

Analysts surveyed by Capital IQ expected $155.2 million.

The company said it now expects 2024 revenue in the range of $640 million to $670 million, up from its prior guidance of $620 million to $650 million. Analysts polled by Capital IQ are looking for $632.2 million.

Shares of Corcept Therapeutics ( CORT ) were up 2.6% in after-hours trading.

Price: 37.49, Change: +0.96, Percent Change: +2.63